Recent Updates
Recently added Catalysts

SAR441566

Phase 2

Psoriasis | Small Molecules | Dermatology |Sanofi|Trials Updated: Jun 23, 2026

SAR441566 development status

Highest phase Phase 2
Registered trials 9 across 1 sponsor since Jul 2022

SAR441566 target and mechanism

ModalitySmall Molecules

Also known as Balinatunfib

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials6
Total Enrollment641

FDA Designations

No designations recorded

SAR441566 clinical trials

SAR441566 · 6 trials · 4 indications

Phase 2 2Phase 1 4
NCT06073093A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisRheumatoid Arthritis
COMPLETED264 Analytics
NCT06073119A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisPsoriasis
COMPLETED221 Analytics
PHASE2COMPLETED
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Rheumatoid ArthritisUnlock trial analytics
PHASE2COMPLETED
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
PsoriasisUnlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12
Baseline to Week 12

ACR20 response criteria is a dichotomous composite endpoint indicating the proportion of participants with at least 20 percent improvement in the number of tender and swollen joints, and in three out of the remaining five ACR core-set measures: patient pain (VAS, No pain to Severe Pain), Patient Global Assessment of disease activity (VAS, Very well to Very Poor), physician global assessment of disease activity (VAS, Very good to Very bad), physical functioning assessment (Health Assessment Questionnaire-Disability Index \[HAQ-DI\]), and acute phase reactants (ESR or CRP mg/dl; in this study CRP will be used). ACR response is scored as a percentage improvement, comparing disease activity at two discrete time points. ACR20 is ≥ 20% improvement.

Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12
Baseline (Day 1) and Week 12

PASI is linear combination of percent of surface area of skin that is affected and severity of erythema(E),induration(i),desquamation(D) over 4 body regions: head(h),trunk(t),upper extremities(u),lower extremities(l). The signs of severity, E, i and D of lesions are assessed using numeric scale for which scores are made independently for each of the areas; range:0 (complete lack of cutaneous involvement) to 4 (severest possible involvement). For each body area, percentage of considered body area covered by plaque psoriasis is translated into numerical value "Ax":0=no involvement,1=\<10% to 6=90 to 100% involvement. These scores are noted Ah, At, Au, and Al in formula below. The PASI score is calculated according to the following formula: PASI = 0.1(Eh+ih+Dh)Ah + 0.3(Et+it+Dt)At + 0.2(Eu+iu+Du)Au + 0.4(El+il+Dl)Al. PASI score range:0 (no disease) to 72 (maximal disease);higher scores: greater psoriasis severity. Percentage of participants with PASI75 at Week 12 is presented.

Change from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic reading
Baseline to day 2
Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1
On-drug Day 8

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 1 is Full range solar ultraviolet B/ultraviolet A (UVB/UVA) \[290 to 400 nm\] exposure.

Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 1
On-drug Day 8

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.

Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 1
On-drug Day 9

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 1 is a Full range solar UVB/UVA \[290 to 400 nm\] exposure.

Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 2
On-drug Day 8

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 2
On-drug Day 8

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 2
On-drug Day 9

The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: Cmax
From Day 1 to Day 5 of each period (5 days per period)

Maximum plasma concentration observed

Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUClast
From Day 1 to Day 5 of each period (5 days per period)

Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time Tlast (AUClast)

Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUC
From Day 1 to Day 5 of each period (5 days per period)

Area under the plasma concentration versus time curve extrapolated to infinity (AUC)

Number of participants with treatment-emergent adverse events (TEAE) including SAE and AESI
Up to 69 days

Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE) including SAE and AESI

Secondary Endpoints

Change from baseline in Disease activity score - C-reactive protein (DAS-28 CRP) at week 12
Baseline to Week 12
Proportion of participants achieving at least 50% improvement from baseline in the ACR score at week 12
Baseline to week 12
Number of participants with Treatment-Emergent Adverse Events (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs)
Baseline to week 14
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SAR441566 dose regimen AEXPERIMENTALParticipant will receive dose regimen A of SAR441566 for 12 weeks
SAR441566 dose regimen BEXPERIMENTALParticipant will receive dose regimen B of SAR441566 for 12 weeks
SAR441566 dose regimen CEXPERIMENTALParticipant will receive dose regimen C of SAR441566 for 12 weeks
SAR441566 dose regimen DEXPERIMENTALParticipant will receive dose regimen D of SAR441566 for 12 weeks
PlaceboPLACEBO_COMPARATORParticipant will receive SAR441566-matching placebo for 12 weeks
SAR441566 dose regimen EEXPERIMENTALParticipants received dose regimen E of SAR441566
Balinatunfib Treatment AEXPERIMENTALParticipants will receive a single oral dose of balinatunfib.
Balinatunfib Treatment BEXPERIMENTALParticipants will receive a single oral dose of balinatunfib.
Moxifloxacin Treatment CACTIVE_COMPARATORParticipants will receive a single oral dose of moxifloxacin.
Placebo Treatment DPLACEBO_COMPARATORParticipants will receive a single oral dose of balinatunfib matching placebo and moxifloxacin matching placebo.
Part I SAR441566 Dose AEXPERIMENTALParticipants will receive repeated low dose of SAR441566 for 7.5 days
Part I SAR441566 Dose BEXPERIMENTALParticipants will receive repeated high dose of SAR441566 for 7.5 days
Part I PlaceboPLACEBO_COMPARATORParticipants will receive repeated SAR441566 matching placebo tablets for 7.5 days
Part II CiprofloxacinACTIVE_COMPARATORParticipants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days
SAR441566EXPERIMENTALParticipants will receive single ascending doses of SAR441566 on day 1 of each 8-12-day cycle

Interventions

NameTypeDescription
SAR441566DRUGTablet
PlaceboDRUGTablet
BalinatunfibDRUGPharmaceutical form: Tablet Route of administration: Oral
MoxifloxacinDRUGPharmaceutical form: Tablet Route of administration: Oral
CiprofloxacinDRUGTablet
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites102

Inclusion Criteria: * Diagnosis of adult-onset RA classified by ACR/EULAR 2010 revised classification criteria for RA of at least 3 months duration, with the onset of signs and symptoms of RA of at least 6 months duration * Moderate-to-severely active RA, defined as: * persistently active diseas...

Countries:United StatesArgentinaBrazilCanadaChileChinaCzechiaGeorgiaGermanyGreeceIndiaJapanMauritiusMexicoPolandPuerto RicoSlovakiaSouth AfricaSpainBulgariaHungaryPortugalTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about SAR441566

What is SAR441566 used for?

SAR441566 is an investigational small molecule developed by Sanofi for the treatment of psoriasis and rheumatoid arthritis. It has been studied in adults with plaque psoriasis and in adults with rheumatoid arthritis, with Phase 2 trials completed in both indications. It is not described as approved for any use.

Who makes SAR441566?

SAR441566 is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of the compound and sponsored the clinical trials evaluating it in plaque psoriasis, rheumatoid arthritis, and healthy volunteers.

What phase is SAR441566 in?

SAR441566 is in Phase 2. Two Phase 2 trials have been completed: one in adults with plaque psoriasis and one in adults with rheumatoid arthritis. Earlier Phase 1 studies in healthy volunteers, including a Japanese male single ascending dose study and a photosafety study, are also completed.

What clinical trials is SAR441566 in?

SAR441566 has been evaluated in completed trials including NCT06073119, a Phase 2 study in plaque psoriasis enrolling 221 adults across 17 countries, and NCT06073093, a Phase 2 study in rheumatoid arthritis enrolling 264 adults. Phase 1 studies include NCT05858788 and NCT05844735 in healthy volunteers.

How many people were enrolled in SAR441566 trials?

Across the listed studies, 334 participants were enrolled in SAR441566 trials. The largest was the Phase 2 rheumatoid arthritis study with 264 participants, followed by the Phase 2 plaque psoriasis study with 221 participants. The Phase 1 photosafety and Japanese single ascending dose studies enrolled 60 and 10 healthy volunteers respectively.

Are SAR441566 trials placebo controlled and blinded?

Yes. The SAR441566 clinical program includes randomized, double-blind, placebo-controlled trials. The Phase 2 studies in plaque psoriasis and rheumatoid arthritis used placebo controls, and a Phase 1 study, NCT05844735, was randomized with both placebo and active comparator arms to evaluate photosafety.